GEFITINIB (G) AND PEMETREXED (PEM) AS A FIRST LINE TREATMENT IN PATIENTS WITH EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY

被引：0
|
作者：
Yoshimura, N. [1 ]
Matsuura, K. [1 ]
Mitsuoka, S. [1 ]
Asai, K. [1 ]
Tochino, Y. [1 ]
Kimura, T. [1 ]
Nakai, M. [1 ]
Mitsukawa, Y. [2 ]
Hirata, K. [1 ]
Kudoh, S. [1 ]
机构：
[1] Osaka City Univ, Sch Med, Dept Resp Med, Osaka 545, Japan
[2] Osaka City Univ Hosp, Dept Pharmaceut, Osaka, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：412 / 413
页数：2
相关论文
共 50 条
  • [1] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
    An, Chaolun
    Zhang, Jiajun
    Chu, Hongjun
    Gu, Chunyan
    Xiao, Feng
    Zhu, Fengwei
    Lu, Rujian
    Shi, Hai
    Zhang, Hongfei
    Yi, Xin
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
  • [2] Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation
    Yoshimura, Naruo
    Kudoh, Shinzoh
    Mitsuoka, Shigeki
    Yoshimoto, Naoki
    Oka, Takako
    Nakai, Toshiyuki
    Suzumira, Tomohiro
    Matusura, Kuniomi
    Tochino, Yoshihiro
    Asai, Kazuhisa
    Kimura, Tatsuo
    Kawaguchi, Tomoya
    Hirata, Kazuto
    [J]. LUNG CANCER, 2015, 90 (01) : 65 - 70
  • [3] Phase III study of gefitinib (G) versus gefitinib plus carboplatin plus pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)
    Seike, M.
    Inoue, A.
    Sugawara, S.
    Morita, S.
    Hosomi, Y.
    Ikeda, S.
    Watanabe, K.
    Takahashi, K.
    Fujita, Y.
    Harada, T.
    Minato, K.
    Takamura, K.
    Kobayashi, K.
    Nukiwa, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 496 - 496
  • [4] First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study.
    Niho, S
    Kubota, K
    Goto, K
    Yoh, K
    Ohmatsu, H
    Kakinuma, R
    Nishiwaki, Y
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 631S - 631S
  • [5] A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study
    Adjei, A. A.
    Mandrekar, S. J.
    Dy, G. K.
    Molina, J. R.
    Adjei, A. A.
    Gandara, D. R.
    Ziegler, K. L. Allen
    Stella, P. J.
    Rowland, K. M., Jr.
    Schild, S. R.
    Zinner, R. G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial
    Gervais, Radj
    Robinet, Gilles
    Clement-Duchene, Christelle
    Denis, Fabrice
    El Kouri, Claude
    Martin, Philippe
    Chouaki, Nadia
    Bourayou, Nawel
    Morere, Jean-Francois
    [J]. LUNG CANCER, 2013, 80 (02) : 185 - 190
  • [7] A phase I study of enzastaurin (Enz) combined with pemetrexed (Pem) in advanced non-small cell lung cancer (NSCLC)
    Takahashi, T.
    Yamamoto, N.
    Murakami, H.
    Ohe, Y.
    Kunitoh, H.
    Nokihara, H.
    Koshiji, M.
    Tamura, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Phase II study of carboplatin and pemetrexed followed by gefitinib for patients with advanced non-small cell lung cancer harboring sensitive EGFR mutation.
    Manabe, Saki
    Oshita, Fumihiro
    Murakami, Shuji
    Kondo, Tetsuro
    Saito, Haruhiro
    Kaneko, Takeshi
    Yamada, Kouzo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
    Ji, Y.
    Wang, X.
    Lou, Z.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979
  • [10] First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib
    Moiseyenko, V.
    Procenko, S. A.
    Levchenko, E. V.
    Barchuk, A. S.
    Matsko, D. E.
    Moiseyenko, F. V.
    Ivantsov, A. O.
    Iyevleva, A. G.
    Mitiushkina, N. V.
    Imyanitov, E. N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345